Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite

Ustekinumab for the treatment of HIV psoriasis

By Paparizos Vasileios   Rallis Efstathios   Kirsten Leuow   Kyriakis Kyriakos  

Journal of Dermatological Treatment, Vol. 23, Iss. 6, 2012-12 ,pp. : 398-399

Informa Healthcare

Access to resources Recommend Favorite

Flare of pustular psoriasis after initiating ustekinumab therapy

By Wenk Kurt S.   Claros Joan M.   Ehrlich Alison  

Journal of Dermatological Treatment, Vol. 23, Iss. 3, 2012-06 ,pp. : 212-214

Informa Healthcare

Access to resources Recommend Favorite

Concurrent treatment of chronic psoriasis and asthma with ustekinumab

By Amarnani Ajay   Rosenthal Ken S.   Mercado Jorge M.   Brodell Robert T.  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 63-66

Informa Healthcare

Access to resources Recommend Favorite

Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2

By Reich Kristian   Schenkel Brad   Zhao Ning   Szapary Philippe   Augustin Matthias   Bourcier Marc   Guenther Lyn   Langley Richard G.  

Journal of Dermatological Treatment, Vol. 22, Iss. 6, 2011-12 ,pp. : 337-347

Informa Healthcare

Access to resources Recommend Favorite